CIK 0001708599 · Non-accelerated filer<br>Smaller reporting company
Serina Therapeutics, Inc.
Sign in to watch- Ticker
- SER
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- AL
- Entity type
- operating
- EIN
- 821436829
- Phone
- (256) 327-9630
- Business address
- 601 GENOME WAY, SUITE 2001, HUNTSVILLE, AL, 35806
- Former names
- AgeX Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 43 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-22 | Simon Farrell Director | Grant or award · Stock Option (right to buy) | +30,500 | 30,500 | ||
| 2026-07-07 | Brannan Stephen K. Director | Purchase | +1,000 | $2.03 | $2K | 1,000 |
| 2026-06-17 | Marshall Richard Peter Director | Grant or award · Stock Option (right to buy) | +15,250 | 15,250 | ||
| 2026-06-17 | Brannan Stephen K. Director | Grant or award · Stock Option (right to buy) | +15,250 | 15,250 | ||
| 2026-06-17 | Venkatesan Jay Director | Conversion | +224,152 | $2.25 | $504K | 231,705 |
| 2026-06-17 | Venkatesan Jay Director | Grant or award · Stock Option (right to buy) | +15,250 | 15,250 | ||
| 2026-06-17 | Venkatesan Jay Director | Conversion · Series A Convertible Preferred Stock | −96,525 | $2.25 | $217K | 0 |
| 2026-06-17 | Bailey Gregory Director | Conversion | +1,770,805 | $2.25 | $4.0M | 1,897,445 |
| 2026-06-17 | Bailey Gregory Director | Conversion | +6,666,667 | $2.25 | $15.0M | 8,564,382 |
| 2026-06-17 | Bailey Gregory Director | Grant or award · Stock Option (right to buy) | +15,250 | 15,250 | ||
| 2026-06-17 | Bailey Gregory Director | Grant or award · Redeemable Warrants | +3,333,333 | 3,333,333 | ||
| 2026-06-17 | Bailey Gregory Director | Conversion · Series A Convertible Preferred Stock | −762,548 | $2.25 | $1.7M | 0 |
| 2026-06-17 | WILSON KAREN J Director | Grant or award · Stock Option (right to buy) | +15,250 | 15,250 | ||
| 2026-06-12 | WILSON KAREN J Director | Purchase | +5,000 | $1.77 | $9K | 10,100 |
| 2026-06-11 | WILSON KAREN J Director | Purchase | +5,100 | $1.75 | $9K | 5,100 |
| 2026-05-26 | LEDGER STEVEN A Chief Executive Officer | Grant or award | +10,100 | $1.93 | $19K | 10,100 |
| 2026-05-22 | Venkatesan Jay Director | Purchase | +589 | $1.78 | $1K | 589 |
| 2026-05-22 | WILSON KAREN J Director | Purchase | +10,000 | $1.93 | $19K | 20,000 |
| 2026-05-21 | Tenjarla Srini SVP, CMC & Formulation | Grant or award · Stock Option (right to buy) | +85,558 | 85,558 | ||
| 2026-05-21 | Moreadith Randall Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +85,558 | 85,558 |
Page 1 of 12 · 223 trades